Richard S Levy
CIK 1454983 · EVP, Chief Drug Dev Officer · last filed 2026-08-04
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
INCY price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
3RD FLOOR
NEW YORK, NY 10014
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| KNSA | Director | 22,359 | $94.11 | $2.10M | $0 | 15 | 2026-08-04 |
| KOD | Director | 1,000 | $99.23 | $99.2K | $44.3K | 10 | 2026-07-02 |
| MDGL | Director | 22,469 | $397.88 | $8.94M | -$19.89M | 23 | 2026-06-18 |
| TARA | Director | 51,000 | $2.42 | $123.4K | $127.6K | 10 | 2026-06-16 |
| CONSTELLATION PHARMACEUTICALS INC (CNST) Delisted | Director | — | $33.99 | — | $0 | 2 | 2021-06-04 |
| INCY | EVP, Chief Drug Dev Officer | 16,926 | $116.34 | $1.97M | -$49.87M | 40 | 2016-01-08 |
10b5-1 Trading Plans
3 plans · 2 in force| Company | Adopted | Sales Can Start | Ends | Plan Allows | Sold So Far | Status | Link |
|---|---|---|---|---|---|---|---|
| MDGL Director |
Feb 20, 2026 | May 21, 2026 | Dec 31, 2026 | 5,682 shares | 5,682 (100%) last filed May 22, 2026 |
Active | 10-Q |
| MDGL Director |
Aug 14, 2025 | Nov 12, 2025 | Dec 31, 2026 | 16,682 shares | 8,500 (51%) last filed Nov 14, 2025 |
Active | 10-Q |
| MDGL Director |
Nov 30, 2023 | Mar 29, 2024 | Ended Jun 16, 2025 | 15,000 shares | 21,000 last filed Nov 8, 2024 |
Ended early | 10-Q |
Recent Filings · Page 8 of 11
106 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2015-09-15 | INCY | Sell (S) | −4,301 | -$559.1K | EDGAR |
| 2015-09-10 | INCY | Mixed | — | -$396.0K | EDGAR |
| 2015-08-10 | INCY | Mixed | — | -$368.5K | EDGAR |
| 2015-07-16 | INCY | Mixed | — | -$7.18M | EDGAR |
| 2015-07-08 | INCY | Mixed | — | -$349.1K | EDGAR |
| 2015-06-23 | INCY | Mixed | — | -$1.81M | EDGAR |
| 2015-06-10 | INCY | Mixed | — | -$351.4K | EDGAR |
| 2015-05-08 | INCY | Mixed | — | -$601.2K | EDGAR |
| 2015-04-08 | INCY | Mixed | — | -$1.76M | EDGAR |
| 2015-03-10 | INCY | Mixed | — | -$1.79M | EDGAR |
10b5-1: the filer ticked the box for trades made under a Rule 10b5-1 trading plan, which sets the sales (or buys) in advance, so they say less about the insider's view at the time than a discretionary trade. The plan's adoption date is shown when the filing's footnotes give it.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment, and an amended or cancelled notice is not listed. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes. Someone who is no longer an officer or director (or never was) files no Form 4, so for them a sale shows up only on a later notice, which lists the seller's sales from the 3 months before it. "No sale on file" means neither record shows one; a dash in Net $ means the value filed on the notice doesn't fit the stock's price (likely a typo).